Probiotics, probioceuticals, pharmabiotics, psychobiotics, immunobiotics, eubiotics, post-biotics...

From Probiotics to Post-biotics - What's in a name?

Expert panel discussion on terms and meanings around probiotics…

 

We shall interactively discuss at this year's IPC, whether the evolving terminology around probiotics still makes sense, and whether consensus can be reached in their use.

Key questions to be addressed by experts: 

  • Do we need subcategories of probiotics? If Yes, based on what grounds?
  • What would be the legislative impact of subcategories of probiotics
(global view - USA, Europe, Asia)
  • Should supporting research be different for these categories?

  • DEFINITION: Do we need subcategories of probiotics? If Yes, based on what grounds?
    ‘Probiotics, probioceuticals, pharmabiotics, psychobiotics, immunobiotics, eubiotics, post-biotics...’, do you have idea of further subcategories? Please, contact us and suggest keywords for the definitions…
     
  • GEOGRAPHY: What would be the legislative impact of subcategories of probiotics
(in the USA, Europe, Asia)
    The purpose is to evaluate what would be the impact if a company would like to launch a product world-wide…
     
  • RESEARCH: Should supporting research be different for these categories?
    Would different names or ‘types’ of ‘probiotics’ also require different types / quality of scientific support? If yes, should we be able to define these requirements (efficacy, safety, target population (healthy/sick; age; nationality), dose, matrix, …)
     
  • MARKETING: Should industry be able to communicate on the different categories and should the legislator determine/actively control the limits of these communications?
    The reason to have the discussion has to do with the international differences that currently exist. EU versus Switzerland, Canada and other countries where legal health claims are allowed. Even within Europe there are differences on how the European legislation is implemented (Italy versus Ireland)…
     
  • ECONOMY:  Is valorization of the results of microbiota research really hampered by the  current communication strategy in Europe?
    As shown in a number of papers, Europe is missing opportunities to significantly reduce health care costs... 

     
    What's in name? - Expert panel discussion on the terms and meanings around probiotics
    Bruno Pot

    Bruno Pot - chair, Director of Business Development, Laboratory of Lactic Acid Bacteria & Mucosal Immunity, Institut Pasteur de Lille, Center for Infection & Immunity of Lille, France

    Read more...

    Carine Lambert

    Carine Lambert,  International Probiotics Association - IPA Europe 

    Read more...

    David Mills

    David A. Mills, Peter J. Shields Endowed Chair in Dairy Food Science, Department of Food Science and Technology, University of California, Davis, USA

    Read more...

     

    Linda Mulder

    Linda MulderWinslove Probiotics, The Netherlands

    Read more...

    Magali Cordillat Simmons

    Magali Cordillat Simmons, Pharmabiotic Research Centre, France

    Read more...

     

    Sin-Hyeog Im

    Sin-Hyeog IM - President of IPC2016
    Institute for Basic Science (IBS) and POSTECH, South Korea

    Read more...